Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bartus R. T., Dean R. L., 3rd, Beer B., Lippa A. S. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982 Jul 30;217(4558):408–414. doi: 10.1126/science.7046051. [DOI] [PubMed] [Google Scholar]
- Chatellier G., Lacomblez L. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine. BMJ. 1990 Feb 24;300(6723):495–499. doi: 10.1136/bmj.300.6723.495. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Davies P., Maloney A. J. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976 Dec 25;2(8000):1403–1403. doi: 10.1016/s0140-6736(76)91936-x. [DOI] [PubMed] [Google Scholar]
- Davis K. L., Thal L. J., Gamzu E. R., Davis C. S., Woolson R. F., Gracon S. I., Drachman D. A., Schneider L. S., Whitehouse P. J., Hoover T. M. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. N Engl J Med. 1992 Oct 29;327(18):1253–1259. doi: 10.1056/NEJM199210293271801. [DOI] [PubMed] [Google Scholar]
- Farlow M., Gracon S. I., Hershey L. A., Lewis K. W., Sadowsky C. H., Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. JAMA. 1992 Nov 11;268(18):2523–2529. [PubMed] [Google Scholar]
- Gauthier S., Bouchard R., Lamontagne A., Bailey P., Bergman H., Ratner J., Tesfaye Y., Saint-Martin M., Bacher Y., Carrier L. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study. N Engl J Med. 1990 May 3;322(18):1272–1276. doi: 10.1056/NEJM199005033221804. [DOI] [PubMed] [Google Scholar]
- Gillis J. C., Benefield P., McTavish D. Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders. Drugs Aging. 1994 Aug;5(2):133–152. doi: 10.2165/00002512-199405020-00007. [DOI] [PubMed] [Google Scholar]
- Gray A., Fenn P. Alzheimer's disease: the burden of the illness in England. Health Trends. 1993;25(1):31–37. [PubMed] [Google Scholar]
- Knapp M. J., Knopman D. S., Solomon P. R., Pendlebury W. W., Davis C. S., Gracon S. I. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA. 1994 Apr 6;271(13):985–991. [PubMed] [Google Scholar]
- Summers W. K., Majovski L. V., Marsh G. M., Tachiki K., Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med. 1986 Nov 13;315(20):1241–1245. doi: 10.1056/NEJM198611133152001. [DOI] [PubMed] [Google Scholar]
- Whitehouse P. J., Price D. L., Clark A. W., Coyle J. T., DeLong M. R. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol. 1981 Aug;10(2):122–126. doi: 10.1002/ana.410100203. [DOI] [PubMed] [Google Scholar]
- Wilcock G. K., Surmon D. J., Scott M., Boyle M., Mulligan K., Neubauer K. A., O'Neill D., Royston V. H. An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease. Age Ageing. 1993 Sep;22(5):316–324. doi: 10.1093/ageing/22.5.316. [DOI] [PubMed] [Google Scholar]